Contents 1. Executive Summary 2. Global Artificial Intelligence in Cancer Market 2.1. Product Overview 2.2. Market Definition 2.3. Segmentation 2.4. Assumptions and Acronyms 3. Research Methodology 3.1. Research Objectives 3.2. Primary Research 3.3. Secondary Research 3.4. Forecast Model 3.5. Market Size Estimation 4. Average Pricing Analysis 5. Macro-Economic Indicators 6. Market Dynamics 6.1. Growth Drivers 6.2. Restraints 6.3. Opportunity 6.4. Trends 7. Correlation & Regression Analysis 7.1. Correlation Matrix 7.2. Regression Matrix 8. Recent Development, Policies & Regulatory Landscape 9. Risk Analysis 9.1. Demand Risk Analysis 9.2. Supply Risk Analysis 10. Global Artificial Intelligence in Cancer Market Analysis 10.1. Porters Five Forces 10.1.1. Threat of New Entrants 10.1.2. Bargaining Power of Suppliers 10.1.3. Threat of Substitutes 10.1.4. Rivalry 10.2. PEST Analysis 10.2.1. Political 10.2.2. Economic 10.2.3. Social 10.2.4. Technological 11. Global Artificial Intelligence in Cancer Market 11.1. Market Size & forecast, 2020A-2030F 11.1.1. By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F 11.1.2. By Volume (Million Units) 2020-2030F; Y-o-Y Growth (%) 2021-2030F 12. Global Artificial Intelligence in Cancer Market: Market Segmentation 12.1. By Regions 12.1.1. North America:(U.S. and Canada), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F 12.1.2. Europe: (Germany, UK, France, Italy, Spain, and Rest of Europe), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F 12.1.3. Asia-Pacific: (China, India, Japan, Australia and Rest of Asia Pacific), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F 12.1.4. Latin America: (Brazil, Mexico, Rest of Latin America), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F 12.1.5. Middle East and Africa, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F 12.2. By Surgery: Market Share (2020-2030F) 12.2.1. Radiotherapy, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F 12.2.2. Chemotherapy, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F 12.2.3. Immunotherapy, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F 12.2.4. Targeted Therapy, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F 12.2.5. Phototherapy, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F 12.2.6. Gene Therapy, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F 12.2.7. Sonodynamic Therapy, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F 12.3. By Cancer type: Market Share (2020-2030F) 12.3.1. Breast cancer, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F 12.3.2. Lung cancer, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F 12.3.3. Melanoma cancer, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F 12.3.4. Colorectal cancer, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F 12.3.5. Prostate cancer, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F 12.3.6. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F 12.4. By End-User: Market Share (2020-2030F) 12.4.1. Diagnosis, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F 12.4.2. Therapy, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F 12.4.3. Prognosis, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F 12.4.4. Health Management, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F 12.4.5. Research, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F 13. Company Profile 14. Microsoft Corporation 14.1. Company Overview 14.2. Company Total Revenue (Financials) 14.3. Market Potential 14.4. Global Presence 14.5. Key Performance Indicators 14.6. SWOT Analysis 14.7. Product Launch 15. NVIDIA 16. IBM 17. Intel 18. Siemens Healthineers 19. GE Healthcare 20. Digital Diagnostics 21. Xilinx 22. InformAI 23. Enlitic 24. Day Zero Diagnostics 25. Aidence 26. Butterfly Network, Inc. 27. Prognos 28. Zebra Medical Vision Consultant Recommendation **The above given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.